Investing Profile

Dan Becker

InvestorVC
Managing Director, Access Biotechnology at Access Industries
accessbio-tech.comNew York, New York
Photo of Dan Becker, Managing Director at Access Industries
Your Intro Paths to Dan Becker

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Networks Dan is a member of
Boston Consulting Group (BCG) Network
277 CONNECTIONS
University of Michigan Network
192 CONNECTIONS
University of Illinois at Urbana-Champaign Network
85 CONNECTIONS
University of Illinois Urbana-Champaign Network
81 CONNECTIONS
Harvard Medical School Network
51 CONNECTIONS

Find Dan Becker on

cb
Current Investing Position
Access Industries Managing Director
Investment Range
$100K - $5.0M
Sweet Spot
$1.5M
Investments On Record
15

Dan Becker is on these Sector & Stage Rankings

Dan Becker's Investments On Record (11)

CompanyStageDateRound SizeTotal Raised
Hemab
Series COct 2025$160M
Series BFeb 2023$140M
$290M
Co-investors: Uya Chuluunbaatar (Amzak Health Investors), Christine Borowski (Access Biotechnology), Joseph Anderson (Sofinnova Partners)
Day One Biopharmaceuticals
Post Ipo EquityJul 2024$180M
Series BFeb 2021$130M
Series AMay 2020$60M
$370M
Co-investors: Julie Grant (Canaan Partners), Michael Gladstone (Atlas Venture), Derek DiRocco (RA Capital Management)
GRO Biosciences
Series BJul 2024$60M
$91M
Co-investors: Ameena El-Bibany (Artis Ventures (AV)), Russ Wilcox (Pillar VC), Geoffrey Smith (Digitalis Ventures), Dror Berman (Innovation Endeavors), Kevin Bitterman (Atlas Venture)
Mariana Oncology
Series BSep 2023$180M
Series ADec 2021$75M
$250M
Co-investors: Kevin Bitterman (Atlas Venture), Geert-Jan Mulder (Forbion), Josh Resnick
Zurp
Pre SeedJan 2023$5M
$5M
Co-investors: Amy Wu (Menlo Ventures), Daniel Darling (Darling Ventures), Niklas Jansen (Headstart Ventures), Julia Lipton (Awesome People Ventures), Lenny Rachitsky (Self-employed), Pascal Unger (Focal), David Weisburd (10X Capital), Siqi Chen (Laserlike Inc), Dhani Jones (Rock Ventures LLC), Bobby Goodlatte (Notable Capital (formerly GGV Capital)), Scott Belsky (A24), Baron Davis, Nik Sharma, Shane Neman
Matchpoint Therapeutics
Series AOct 2022$70M
$100M
Co-investors: Bruce Booth (Atlas Venture), Jason P. Hafler (Sanofi Ventures)
ACELYRIN
Series CSep 2022$300M
$560M
Co-investors: Beth Seidenberg (Kleiner Perkins), Richard Gaster (venBio), Sean Harper
Curie Therapeutics
Series ADec 2021$75M
$75M
Co-investors: Kevin Bitterman (Atlas Venture)

Dan Becker's Experience

Internal Medicine Resident Brigham and Women's HospitalPresent
Nephrology Fellow Brigham and Women's HospitalPresent
Research Fellow Harvard Medical SchoolPresent
Principal Boston Consulting Group (BCG)Present
Principal New Leaf Venture PartnersPresent
Board Member Principia BiopharmaPresent
Managing Director, Access Biotechnology Access IndustriesPresent
Board Member Day One BiopharmaceuticalsPresent
Board Member Pandion TherapeuticsPresent
Board Member Perfuse TherapeuticsPresent
Board Member Mariana OncologyPresent
Board Member ACELYRIN, INC.Present
Board Member Hemab TherapeuticsPresent
Board Chair Pandion TherapeuticsPresent
Board Member Zura Bio Limited (Nasdaq: ZURA)Present

Dan Becker's Education

University of Michigan PhD Cellular and Molecular Biology
University of Illinois at Urbana-Champaign BS Physiology
University of Michigan Medical School MD With Distinction, With Distinction in Research
University of Illinois Urbana-Champaign BS Physiology